Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of UCB5857 in activated PI3K delta syndrome
2015-005541-30Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of seletalisib in Activated PI3Kδ syndrome (APDS), sponsored by UCB. Primary endpoint: Treatment-emergent adverse events. Started Apr 2016; status: completed.
02
Drugs
seletalisib
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on 2015-005541-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005541-30.